Portfolio company
Kronos Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
About
This biopharmaceutical company develops small molecule therapeutics targeting transcription factors for patients with cancer and autoimmune diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Biopharmaceutical company
This firm develops small molecule drugs targeting protein regulatory sites to treat patients with cancer and autoimmune diseases.
Kezar Life Sciences
This clinical-stage biopharmaceutical company develops small-molecule therapeutics for patients with autoimmune diseases and inflammatory conditions.
Auron Therapeutics
This company develops small-molecule drugs using an AI-powered platform to treat patients with cancer and inflammatory diseases.
Eikon Therapeutics
This biopharmaceutical company develops small molecule medicines for patients with cancer and other serious diseases using a live-cell imaging drug discovery platform.
Frontier Medicines
This biopharmaceutical company develops small-molecule precision medicines targeting undruggable proteins for patients with cancer and immunological diseases.
Biotheryx
The company develops protein degrader medicines for patients with cancer and inflammatory diseases.
Talus Bio
The company develops a drug discovery platform that identifies transcription factor modulators for pharmaceutical and biotechnology partners seeking to treat cancers and other diseases.
Kymera Therapeutics
This biotechnology company develops small molecule medicines that degrade disease-causing proteins for patients with cancer and immune-inflammatory diseases.